Welcome to the e-CCO Library!

P534: Spontaneous intra-abdominal abscess in Crohn's disease: Efficacy of non-surgical management and prognostic factors
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Labidi1*, S. Hamdi1, M. Ben Abbes1, N. Ben Mustapha1, M. Hafi1, H. Maghrebi2, M. Fekih1, L. Zouiten1, M. Serghini1, J. Boubaker1

Created: Thursday, 21 February 2019, 9:14 AM
P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

X. Roblin1, A. Serone2, O.K. Yoon3, L. Zhuo3, E. Grant4, J. Woo5, J. Liu3, R. Galien6, G. D’Haens7

Created: Thursday, 30 January 2020, 10:12 AM
P535: Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre study
Year: 2022
Source: ECCO'22
Authors: Aleman Gonzalez, H.(1);Sankaranarayanan, R.(1);Pattinson, A.(1);Turnbull, J.(1);Katie, S.(1);Whitehead, E.(1);Talbot, A.(1);Myers, S.(1);Sebastian, S.(1);
Created: Friday, 11 February 2022, 3:56 PM
P535: Azathioprine vs. mesalamine for prevention of post-operative clinical relapse in Crohn’s disease patients with severe endoscopic recurrence: data on efficacy and safety from an IG-IBD multi-centre randomised double-blind double-dummy trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Orlando*1, F. Mocciaro2, M. Ventimiglia1, S. Renna1, D. Scimeca2, A. Rispo3, M. L. Scribano4, A. Testa3, A. Aratari5, F. Bossa6, E. Angelucci7, S. Onali8, M. Cappello9, M. Giunta10, F. Castiglione3, C. Papi5, V. Annese6, L. Biancone8, A. Kohn4, R. Di Mitri2, M. Cottone11

Created: Friday, 22 February 2019, 9:41 AM
P535: COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liu, Z.(1)*;Alexander, J.(1);Le, K.(1);Zhou, X.(1);Ibraheim, H.(1);Anandabaskaran, S.(1);Saifuddin, A.(1);Lin, K.(2);Mcfarlane, L.(2);Anand, N.(1);Constable, L.(1);Castro-Seoane, R.(1);Nice, R.(3);Bewshea, C.(3);D'Mello, A.(4);Jones, G.R.(5);Balarajah, S.(1);Fiorentino, F.(6);Sebastian, S.(7);Irving, P.(8);Hicks, L.(1);Williams, H.(1);Kent, A.(9);Linger, R.(10);Parkes, M.(11);Kok, K.(12);Patel, K.V.(13);Teare, J.(14);Altmann, D.(15);Hart, A.(16);Lees, C.(5);Boyton, R.(15);Goodhand, J.(3);Kennedy, N.(3);Pollock, K.(2);Ahmad, T.(3);Powell, N.(1);
Created: Friday, 14 July 2023, 11:05 AM
P535: Optimising vedolizumab in treatment sequences for Crohn’s disease: Results from a simulation model using real-world evidence
Year: 2021
Source: ECCO'21 Virtual
Authors: Louis, E.(1);Nikolaou, A.(2);Litkiewicz, M.(2);Agboton, C.(3);Wang, S.(4);Armuzzi, A.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P535: Outcomes of endoscopic resections of large non-polypoid lesions inflammatory bowel disease: a single United Kingdom centre experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gulati S., Emmanuel A., Burt M., Hayee B., Haji A.

Created: Wednesday, 20 February 2019, 10:36 AM
P535: The use of therapeutic drug monitoring for infliximab and adalimumab in inflammatory bowel disease: Practice patterns, understanding and interpretation
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.A. Samaan*, P.M. Irving

Created: Thursday, 21 February 2019, 9:14 AM
P536 Early prediction of intravenous corticosteroid therapy failure in moderate–severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Croft1, A. Lord2, G. Radford-Smith1

Created: Thursday, 30 January 2020, 10:12 AM
P536: Combination therapy of bone marrow mesenchymal stromal cells and azathioprine not affect the clinical course luminal Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Knyazev O.*1, Parfenov A.1, Fadeeva N.1,2, Konoplyannikov A.3, Kagramanova A.1, Ruchkina I.1

Created: Wednesday, 20 February 2019, 10:36 AM
P536: Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Yüksel, I.(1,2);Baspınar, B.(1);Durak, M.B.(1);Kilic, V.(1);Kivrakoglu, F.(1,2);Guven, I.E.(1);Kosar, K.(1);Erdogan, C.(1);Alkan, A.(3);
Created: Friday, 11 February 2022, 3:56 PM
P536: Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Morales Bermúdez, A.I.(1);Bravo Aranda, A.M.(1);Martinez Burgos, M.(1);Olmedo Martín, R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P536: Is there any association between fat body mass and bone mineral density in patients with Inflammatory Bowel Disease?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ratajczak, A.E.(1)*;Michalak, M.(2);Szymczak-Tomczak, A.(1);Rychter, A.M.(1);Zawada, A.(1);Skoracka, K.(1);Dobrowolska, A.(1);Krela-Kaźmierczak, I.(1);
Created: Friday, 14 July 2023, 11:05 AM
P536: Minimally invasive gasless technique for ileocolic resection using an existing McBurney incision
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Fazzolari1, G. Bagaglini1, S. D'Ugo1,2*, B. Sensi1, A. Di Giorgio1, G. Sica1

Created: Thursday, 21 February 2019, 9:14 AM
P536: Thiopurine metabolite levels in pregnant IBD patients and infants following intrauterine thiopurine exposure
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Flanagan*1, A. Ross1, A. L. Hamilton1, S. J. Bell1

Created: Friday, 22 February 2019, 9:41 AM
P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.I. Iborra Colomino1, B. Beltrán1, A. Fernández-Clotet2, E. Iglesias Flores3, P. Navarro4, M. Rivero5, A. Gutiérrez6, M. Sierra-Ausin7, F. Mesonero8, R. Ferreiro-Iglesias9, J. Hinojosa10, X. Calvet11, B. Sicilia12, C. González-Muñoza13, B. Antolín14, M. González Vivo15, A.Y. Carbajo16, S. García17, A. Martín-Cardona18, G. Surís Marín19, M.D. Martín-Arranz20, R. De Francisco21, F. Cañete22, T. Carlos23, F. Gomollón24, R. Lorente25, I. Rodríguez-Lago26, A. Forés-Bosch27, E. Bernardos28, L. Ramos29, P. Delgado30, A. Hernández31, M. Van Domselaar32, D. Hervás33, E. Domènech34, P. Nos1

Created: Thursday, 30 January 2020, 10:12 AM
P537: Adalimumab: Relevance of drug trough levels and antibodies assessment in the prognosis of Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Perdigoto, C. Macedo*, F. Portela, S. Lopes, M. Ferreira, S. Mendes, M. Ferreira, L. Tomé

Created: Thursday, 21 February 2019, 9:14 AM
P537: Anemia in Crohn's Disease: Response to treatment and risk of recurrence
Year: 2021
Source: ECCO'21 Virtual
Authors: Gharbi, G.(1);Bibani, N.(1);Sabbah, M.(1);Nawel, B.(1);Trad, D.(1);Ouakaa, A.(1);Elloumi, H.(1);Gargouri, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P537: Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Subramaniam K.*1,2, Watthayalage R.1, Neeman T.3, Pavli P.1,2

Created: Wednesday, 20 February 2019, 10:36 AM